ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,310.40
-0.20%
S&P ASX All Technology
3,765.60
-0.15%
Brent Oil
80.005
0.00%
US Dollar vs AUD
1.61499
-0.02%
Bitcoin
103,443.08
-0.66%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Seres Therapeutics Inc (MCRB)

  7. Seres Therapeutics Inc (MCRB) News

MCRB

Seres Therapeutics (MCRB)

Seres Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MCRB
DateTimeSourceHeadlineSymbolCompany
16/01/202523:00GlobeNewswire Inc.Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST SaleNASDAQ:MCRBSeres Therapeutics Inc
14/01/202500:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
10/01/202523:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
09/01/202523:00GlobeNewswire Inc.Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate UpdatesNASDAQ:MCRBSeres Therapeutics Inc
16/12/202423:00GlobeNewswire Inc.Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
09/12/202423:00GlobeNewswire Inc.FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)NASDAQ:MCRBSeres Therapeutics Inc
22/11/202423:00GlobeNewswire Inc.Seres Therapeutics to Participate in Piper Sandler Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
20/11/202408:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
20/11/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
20/11/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
20/11/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
14/11/202402:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MCRBSeres Therapeutics Inc
14/11/202400:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
13/11/202423:00GlobeNewswire Inc.Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:MCRBSeres Therapeutics Inc
06/11/202423:00GlobeNewswire Inc.Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024NASDAQ:MCRBSeres Therapeutics Inc
30/10/202409:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
30/10/202409:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
30/10/202409:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
30/10/202409:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MCRBSeres Therapeutics Inc
15/10/202415:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MCRBSeres Therapeutics Inc
12/10/202407:34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MCRBSeres Therapeutics Inc
02/10/202406:46Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MCRBSeres Therapeutics Inc
02/10/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
01/10/202407:15GlobeNewswire Inc.Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.ANASDAQ:MCRBSeres Therapeutics Inc
27/09/202406:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
27/09/202406:01GlobeNewswire Inc.Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30NASDAQ:MCRBSeres Therapeutics Inc
13/09/202421:00GlobeNewswire Inc.Seres Therapeutics to Participate in Cantor 2024 Global Healthcare ConferenceNASDAQ:MCRBSeres Therapeutics Inc
12/09/202422:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MCRBSeres Therapeutics Inc
12/09/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
12/09/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MCRBSeres Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MCRB

Your Recent History

BIT
COMGFB
Compam Fund Global Flexi...
BIT
I09303
Intesa Sanpaolo
BIT
1LMT
Lockheed Martin
BIT
F19797
Vontobel Financial Produ...
BIT
S31303
Societe Generale Effekten
BIT
Q00576
Leonteq Securities
BIT
I05386
Banca IMI
BIT
3SSQ
Graniteshares 3x Short S...
BIT
CEU
Amundi Index MSCI Europe...
BIT
UB0JNS
UniCredit Bank
BIT
I10448
IT0005615858 20250602 14.5
BIT
P1HL75
BNP Paribas Issuance
BIT
GGRE
ETF
BIT
XUTC
Xtrackers MSCI USA Infor...
BIT
P11PZ5
BNP PARIBAS ISSUANCE
BIT
ESEH
BNP Paribas Theam S&P 50...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads